Leerink Partners Maintains Outperform on Viridian Therapeutics, Raises Price Target to $54
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Leerink Partners analyst Thomas Smith maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $50 to $54.
Leerink Partners analyst Thomas Smith maintains Viridian Therapeutics (NASDAQ:VRDN) with a Outperform and raises the price target from $50 to $54.